Can insignificant prostate cancer be predicted preoperatively in men with stage T1 disease?

Research output: Contribution to journalArticle

Abstract

This study reviews the pathological findings in nonpalpable prostate cancer detected on transurethral resection (TUR) (stages T1a and T1b) and on needle biopsy (stage T1c) to determine whether insignificant cancers can be predicted preoperatively. The majority of stage T1a cancers are insignificant and all stage T1b cancers are significant. Preoperative pathological parameters cannot identify the minority of T1a cancers that are more significant and the minority of T1b cancers with relatively little residual cancer. Although most nonpalpable tumors diagnosed by screening techniques are usually significant tumors, which would be treated aggressively if they were palpable, 12% to 25% of cancers removed from nonpalpable disease are relatively insignificant. There is conflicting data as to whether a combination of needle biopsy findings and PSA density measurements can aid in the prediction of insignificant cancers. If conservative management is considered, a patient should undergo repeat biopsies (including transition zone biopsies) to detect those more significant cancers that may have been undersampled. In addition, serial serum PSA measurements should be performed to detect whether serum PSA levels increase to a point where these tumors would be reclassified as significant. When planning therapy for T1 patients, the age, comorbidity, and treatment preferences of the patient are key factors that must also be taken into account.

Original languageEnglish (US)
Pages (from-to)165-173
Number of pages9
JournalSeminars in Urologic Oncology
Volume14
Issue number3
StatePublished - 1996

Fingerprint

Prostatic Neoplasms
Neoplasms
Needle Biopsy
Biopsy
Patient Preference
Residual Neoplasm
Serum
Comorbidity
Therapeutics

Keywords

  • prostate cancer
  • stage T1a
  • stage T1b
  • Stage T1c

ASJC Scopus subject areas

  • Urology

Cite this

Can insignificant prostate cancer be predicted preoperatively in men with stage T1 disease? / Epstein, Jonathan Ira.

In: Seminars in Urologic Oncology, Vol. 14, No. 3, 1996, p. 165-173.

Research output: Contribution to journalArticle

@article{b983392a4dc84a8ba0451c99bd2c5ee9,
title = "Can insignificant prostate cancer be predicted preoperatively in men with stage T1 disease?",
abstract = "This study reviews the pathological findings in nonpalpable prostate cancer detected on transurethral resection (TUR) (stages T1a and T1b) and on needle biopsy (stage T1c) to determine whether insignificant cancers can be predicted preoperatively. The majority of stage T1a cancers are insignificant and all stage T1b cancers are significant. Preoperative pathological parameters cannot identify the minority of T1a cancers that are more significant and the minority of T1b cancers with relatively little residual cancer. Although most nonpalpable tumors diagnosed by screening techniques are usually significant tumors, which would be treated aggressively if they were palpable, 12{\%} to 25{\%} of cancers removed from nonpalpable disease are relatively insignificant. There is conflicting data as to whether a combination of needle biopsy findings and PSA density measurements can aid in the prediction of insignificant cancers. If conservative management is considered, a patient should undergo repeat biopsies (including transition zone biopsies) to detect those more significant cancers that may have been undersampled. In addition, serial serum PSA measurements should be performed to detect whether serum PSA levels increase to a point where these tumors would be reclassified as significant. When planning therapy for T1 patients, the age, comorbidity, and treatment preferences of the patient are key factors that must also be taken into account.",
keywords = "prostate cancer, stage T1a, stage T1b, Stage T1c",
author = "Epstein, {Jonathan Ira}",
year = "1996",
language = "English (US)",
volume = "14",
pages = "165--173",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Can insignificant prostate cancer be predicted preoperatively in men with stage T1 disease?

AU - Epstein, Jonathan Ira

PY - 1996

Y1 - 1996

N2 - This study reviews the pathological findings in nonpalpable prostate cancer detected on transurethral resection (TUR) (stages T1a and T1b) and on needle biopsy (stage T1c) to determine whether insignificant cancers can be predicted preoperatively. The majority of stage T1a cancers are insignificant and all stage T1b cancers are significant. Preoperative pathological parameters cannot identify the minority of T1a cancers that are more significant and the minority of T1b cancers with relatively little residual cancer. Although most nonpalpable tumors diagnosed by screening techniques are usually significant tumors, which would be treated aggressively if they were palpable, 12% to 25% of cancers removed from nonpalpable disease are relatively insignificant. There is conflicting data as to whether a combination of needle biopsy findings and PSA density measurements can aid in the prediction of insignificant cancers. If conservative management is considered, a patient should undergo repeat biopsies (including transition zone biopsies) to detect those more significant cancers that may have been undersampled. In addition, serial serum PSA measurements should be performed to detect whether serum PSA levels increase to a point where these tumors would be reclassified as significant. When planning therapy for T1 patients, the age, comorbidity, and treatment preferences of the patient are key factors that must also be taken into account.

AB - This study reviews the pathological findings in nonpalpable prostate cancer detected on transurethral resection (TUR) (stages T1a and T1b) and on needle biopsy (stage T1c) to determine whether insignificant cancers can be predicted preoperatively. The majority of stage T1a cancers are insignificant and all stage T1b cancers are significant. Preoperative pathological parameters cannot identify the minority of T1a cancers that are more significant and the minority of T1b cancers with relatively little residual cancer. Although most nonpalpable tumors diagnosed by screening techniques are usually significant tumors, which would be treated aggressively if they were palpable, 12% to 25% of cancers removed from nonpalpable disease are relatively insignificant. There is conflicting data as to whether a combination of needle biopsy findings and PSA density measurements can aid in the prediction of insignificant cancers. If conservative management is considered, a patient should undergo repeat biopsies (including transition zone biopsies) to detect those more significant cancers that may have been undersampled. In addition, serial serum PSA measurements should be performed to detect whether serum PSA levels increase to a point where these tumors would be reclassified as significant. When planning therapy for T1 patients, the age, comorbidity, and treatment preferences of the patient are key factors that must also be taken into account.

KW - prostate cancer

KW - stage T1a

KW - stage T1b

KW - Stage T1c

UR - http://www.scopus.com/inward/record.url?scp=0029782841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029782841&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 165

EP - 173

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 3

ER -